SCHEDULE: NovaBay Appoints David Lazar CEO, Secures $6M Investment

David E. Lazar has been appointed CEO and a director of NovaBay Pharmaceuticals, Inc., following a $3.85 million investment and an agreement for an additional $2.15 million, significantly increasing his stake to 19.99%.

Summary

• David E. Lazar has been appointed Chief Executive Officer and a member of NovaBay Pharmaceuticals, Inc.'s Board of Directors, effective August 19, 2025.
• Justin Hall resigned as CEO but will remain Vice President of Business Development, General Counsel, Corporate Secretary, and a Board member.
• Lazar acquired Series D Convertible Preferred Stock for $3.85 million, convertible into 77.0 million shares of Common Stock.
• He also agreed to purchase Series E Convertible Preferred Stock for an additional $2.15 million at a subsequent closing, convertible into 43.0 million shares of Common Stock, subject to stockholder approval and other conditions.
• Lazar currently beneficially owns 1,200,048 shares, representing approximately 19.99% of the outstanding Common Stock.
• A Voting Agreement was established with Poplar Entities, granting Lazar shared voting power over 1,020,300 shares and including a standstill provision for the Poplar Entities.
• Lazar has contractual rights to recommend and nominate directors to the Board, and potentially be appointed Board Chair, contingent on beneficial ownership levels and stockholder approval.
• The Preferred Stock includes full ratchet protection in any subsequent offerings.
• The Issuer is obligated to hold a special meeting for stockholder approval on several matters, including the issuance of shares, a reverse stock split, and an increase in authorized shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant capital infusion and a major leadership change, which can be positive for a company seeking revitalization. However, the reliance on future stockholder approval for the full investment and governance changes, along with the need for a reverse stock split, introduces elements of uncertainty and suggests underlying challenges.

Positives

• New leadership with David E. Lazar as CEO and Board member, potentially bringing fresh strategic direction.
• Significant capital injection of $3.85 million immediately, with an additional $2.15 million committed, totaling $6 million, providing financial support for operations.
• The investment demonstrates a strong belief in the company's value, as Lazar purchased shares based on his belief they were undervalued.
• Full ratchet protection for the Preferred Stock in future offerings protects Lazar's investment from dilution.
• The Voting Agreement secures support from Poplar Entities for key proposals, ensuring smoother governance.

Negatives

• The full conversion of preferred stock and the additional $2.15 million investment are subject to stockholder approval, introducing uncertainty and potential delays.
• The 19.99% beneficial ownership limitation without stockholder approval restricts the immediate impact of the full investment.
• The need for a reverse stock split and an increase in authorized shares suggests potential issues with share price or capital structure that require significant adjustments.
• The resignation of the previous CEO, Justin Hall, from his top executive role, while remaining on the board and in other roles, could signal a period of transition and potential disruption.

Risks

• Stockholder Approval Risk: The acquisition of Series E Preferred Stock and the full conversion of both Series D and Series E Preferred Stock are contingent on obtaining Stockholder Approval, which may not be granted.
• Beneficial Ownership Limitation: Without Stockholder Approval, the conversion of Preferred Stock is limited to 19.99% of outstanding Common Stock, restricting the immediate impact of the investment.
• Market Conditions: Future investment decisions by the Reporting Person depend on overall market conditions, other investment opportunities, and share prices, which could lead to changes in his position.
• Operational and Financial Performance: The Reporting Person's ongoing review of his investment is contingent on the Issuer's financial position and investment strategy, implying a risk if performance does not meet expectations.
• Dilution Risk: While the preferred stock has full ratchet protection, the issuance of a large number of new shares upon conversion (up to 120 million shares) could significantly dilute existing common stockholders if not managed effectively.
• Governance Changes: Significant changes to the Board of Directors and management structure are planned, which could lead to instability or unforeseen challenges during the transition period.

Future Outlook

The Reporting Person intends to review his investment in the Issuer on a continuing basis and may increase or decrease his position, engage in discussions with management and stockholders, propose business combinations or dispositions, or suggest improvements to financial and operational performance. The Issuer is committed to holding a special meeting of stockholders to approve various corporate actions, including the issuance of shares, a reverse stock split, and an increase in authorized shares, which are crucial for the full realization of the investment and governance changes.

Management Comments

• "The Reporting Person purchased the Shares based on the Reporting Person's belief that the Shares, when purchased, were undervalued and represented an attractive investment opportunity."

Industry Context

This filing indicates a significant leadership and capital infusion event for NovaBay Pharmaceuticals. In the pharmaceutical industry, such investments and management changes often signal a strategic pivot or an attempt to revitalize a company, especially if it has been underperforming or seeking new growth avenues. The "full ratchet protection" on preferred stock suggests a cautious investor seeking strong downside protection, which is common in high-risk, high-reward sectors like biotech/pharma. The need for a reverse stock split and increased authorized shares could imply a need to improve stock market perception or facilitate future capital raises, a common challenge for smaller pharmaceutical companies.

Comparison to Industry Standards

• The 19.99% beneficial ownership limitation without stockholder approval is a standard NYSE American rule to prevent significant control changes without shareholder consent, aligning with typical corporate governance practices for public companies.
• The "full ratchet protection" on convertible preferred stock is a strong anti-dilution provision, often seen in venture capital or distressed investments, providing the investor with significant protection against future equity issuances at lower valuations, which is a more aggressive term than typically found in standard public market preferred stock offerings.
• The appointment of a significant investor as CEO is a common strategy in turnaround situations or when a major shareholder seeks direct operational control to implement their vision, similar to situations seen with activist investors taking board seats or executive roles in companies like Icahn Enterprises' involvement in various companies.

Management Changes

Corporate Governance

Related Party Transactions

• The Securities Purchase Agreement (SPA) between the Issuer and David E. Lazar, who is now the CEO and a director, constitutes a related party transaction.
• The Voting Agreement between the Issuer, David E. Lazar, and the Poplar Entities, where Lazar has shared voting power, could be considered a related party arrangement given Lazar's new role.

Stakeholder Impact

• Shareholders: Potential for significant dilution from the conversion of preferred stock (up to 120 million shares) if not managed by a reverse stock split. Opportunity for value creation under new leadership and with new capital. Voting on key corporate actions will be critical.
• Employees: Change in CEO and potential strategic shifts could impact organizational structure and priorities. Justin Hall's transition to other executive roles suggests continuity in some areas.
• Creditors: The capital infusion of $6 million could improve the company's financial stability, potentially reducing credit risk.
• Customers: Strategic changes under new leadership might lead to new product development or market approaches, potentially impacting customer offerings.

Next Steps

• Issuer to hold a special meeting of stockholders to obtain approval for: issuance of shares upon conversion of Preferred Stock; a reverse stock split of the Common Stock; an increase in the authorized shares of Common Stock; an amendment to the Issuer's equity incentive plan; an increase in the Issuer's authorized shares of preferred stock; the election of certain directors to the Issuer's board of directors; and approval of equity consideration to resigning non-employee directors.
• Subsequent closing ("Final Closing") for the purchase of Series E Preferred Stock by David E. Lazar, contingent on Stockholder Approval and other conditions.
• David E. Lazar may increase or decrease his position in the Issuer based on market conditions and other factors.
• David E. Lazar may engage in further communications with management and the Board, discuss potential business combinations, or make recommendations for improving performance.

Key Dates

Recommendation

The filing presents a mixed bag of significant capital infusion and a major leadership change, which are generally positive for a company seeking revitalization. However, the full realization of the investment and governance changes is contingent on future stockholder approval, introducing uncertainty. The need for a reverse stock split and an increase in authorized shares suggests underlying challenges that need to be addressed. While the new CEO's belief in undervaluation is positive, the immediate impact is limited by the 19.99% beneficial ownership cap. Investors should hold to observe the outcome of the stockholder meeting, the full capital deployment, and the initial strategic direction under the new leadership before making further investment decisions.

Keywords

NovaBay Pharmaceuticals, David E. Lazar, CEO Appointment, SEC Schedule 13D, Convertible Preferred Stock, Equity Investment, Corporate Governance, Stockholder Approval, Reverse Stock Split, Board of Directors, Voting Agreement, Beneficial Ownership, NVBY